Jade Biosciences, Inc. (JBIO)
NCM – Real vaqt narxi. Valyuta: USD
22.00
+0.19 (0.87%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
22.00
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:00 PM EDT
Find any stock by ticker or company name

NCM – Real vaqt narxi. Valyuta: USD
22.00
+0.19 (0.87%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
22.00
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:00 PM EDT
Jade Biosciences, Inc. yallanish va immunologiya ko'rsatkichlari uchun davolash usullarini ishlab chiqadigan biotexnologiya kompaniyasi sifatida faoliyat yuritadi, ayniqsa autoimmün kasalliklari bilan kasallangan bemorlarda. Kompaniya JADE101ni ishlab chiqmoqda, bu A PRoliferation Inducing Ligand oqsilini blokirovka qilish uchun mo'ljallangan monoklonal antidir, u 1-faza klinik sinovlarida. Kompaniya, shuningdek, preklinik rivojlanish bosqichida bo'lgan JADE201 va JADE-003ni ishlab chiqmoqda. Jade Biosciences, Inc. Paragon Therapeutics, Inc. bilan hamkorlik shartnomasiga ega. Jade Biosciences, Inc. Uoltem, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew James King BVMS, D.V.M., Ph.D. | President of Research & Development |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
| Mr. Bradford D. Dahms Ph.D. | CFO & Treasurer |
| Mr. Jonathan Quick | Senior Vice President of Finance |
| Mr. Tom Frohlich | President, CEO & Director |
| Ms. Amy Sullivan | Senior Vice President of Development Operations |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 8-K | d127137d8k.htm |
| 2026-06-11 | 8-K | d161530d8k.htm |
| 2026-06-05 | DEFA14A | d151042ddefa14a.htm |
| 2026-06-04 | 8-K | d103726d8k.htm |
| 2026-06-01 | 8-K | d124589d8k.htm |
| 2026-05-13 | CORRESP | filename1.htm |
| 2026-05-07 | S-8 | d61004ds8.htm |
| 2026-05-07 | 10-Q | ck0001798749-20260331.htm |
| 2026-04-28 | DEFA14A | d116556ddefa14a.htm |
| 2026-04-28 | DEF 14A | d52810ddef14a.htm |
| Ms. Elizabeth Balta J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Lori Stewart | Senior Vice President of People |
| Ms. Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy |
| Ms. Valerie Fauvelle | Senior Vice President of Regulatory & Quality |